Are These Drugs Destined to Fail Again?
Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Motley Fool health care analyst Brenton Flynn talks about two drugs in the Alzheimer's disease space, one from Eli Lilly and one from Merck , that are both progressing to further trials in a space notorious for failure. Will we see positive results from these drugs, or is their fate already sealed?
Success in Alzheimer's is particularly important for Eli Lilly, which will see nearly $0.40 of every $1.00 in sales exposed to generic competition in coming years. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.
The article Are These Drugs Destined to Fail Again? originally appeared on Fool.com.Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.